American Journal of Cardiology
Volume 106, Issue 6 , Pages 774-779 , 15 September 2010

Effect of Coronary Target Lesion Revascularization on Late Cardiac Events After Insertion of Sirolimus-Eluting or Bare Metal Stents

  • Victor Novack, MD, PhD

      Affiliations

    • Harvard Clinical Research Institute, Boston, Massachusetts
    • Dr. Novack and Dr. Nguyen contributed equally to this article.
    • ,
  • Michael C. Nguyen, MBBS

      Affiliations

    • Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts
    • Dr. Novack and Dr. Nguyen contributed equally to this article.
    • ,
  • Meredith Rooney, MD

      Affiliations

    • Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts
    • ,
  • Riya Chacko, MD

      Affiliations

    • Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts
    • ,
  • Lena Novack, PhD

      Affiliations

    • Harvard Clinical Research Institute, Boston, Massachusetts
    • ,
  • Michael Pencina, PhD

      Affiliations

    • Harvard Clinical Research Institute, Boston, Massachusetts
    • ,
  • Patricia Apruzzese, MA

      Affiliations

    • Harvard Clinical Research Institute, Boston, Massachusetts
    • ,
  • Laura Mauri, MD, MSc

      Affiliations

    • Harvard Clinical Research Institute, Boston, Massachusetts
    • ,
  • Sidney A. Cohen, MD, PhD

      Affiliations

    • Cordis Inc., Warren, New Jersey; Division of Cardiology, Hospital of University of Pennsylvania, Philadelphia, Pennsylvania
    • ,
  • Jeffrey Moses, MD

      Affiliations

    • Columbia University Medical Center and the Cardiovascular Research Foundation, New York, New York
    • ,
  • Martin B. Leon, MD

      Affiliations

    • Columbia University Medical Center and the Cardiovascular Research Foundation, New York, New York
    • ,
  • Donald E. Cutlip, MD

      Affiliations

    • Harvard Clinical Research Institute, Boston, Massachusetts
    • Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts
    • Corresponding Author InformationCorresponding author: Tel: (617) 632-7455; fax: (617) 632-7460

Received 14 March 2010 ,Accepted 26 April 2010.

References 

  1. Chen MS, John JM, Chew DP, Lee DS, Ellis SG, Bhatt DL. Bare metal stent restenosis is not a benign clinical entity. Am Heart J. 2006;151:1260–1264
  2. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315–1323
  3. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004;350:221–231
  4. Lagerqvist B, James SK, Stenestrand U, Lindback J, Nilsson T, Wallentin L. Long-term outcomes with drug-eluting stents versus Bare-metal stents in Sweden. N Engl J Med. 2007;356:1009–1019
  5. Nordmann AJ, Briel M, Bucher HC. Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis. Eur Heart J. 2006;27:2784–2814
  6. Camenzind E, Steg PG, Wijns W. Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. Circulation. 2007;115:1440–1456
  7. Pfisterer M, Brunner-La Rocca HP, Buser PT, Rickenbacher P, Hunziker P, Mueller C, et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus Bare-metal stents. J Am Coll Cardiol. 2006;48:2584–2591
  8. Mauri L, Hsieh WH, Massaro JM, Ho KK, D'Agostino R, Cutlip DE. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med. 2007;356:1020–1029
  9. Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med. 2007;356:998–1008
  10. Stone GW, Ellis SG, Colombo A, Dawkins KD, Grube E, Cutlip DE, et al. Offsetting impact of thrombosis and restenosis on the occurrence of death and myocardial infarction after paclitaxel-eluting and bare metal stent implantation. Circulation. 2007;115:2842–2847
  11. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115:2344–2351
  12. Thygesen K, Alpert JS, White HD, Jaffe AS, Apple FS, Galvani M, et al. Universal definition of myocardial infarction. Circulation. 2007;116:2634–2653
  13. Kastrati A, Schomig A, Elezi S, Schuhlen H, Dirschinger J, Hadamitzky M, et al. Predictive factors of restenosis after coronary stent placement. J Am Coll Cardiol. 1997;30:1428–1436
  14. Cutlip DE, Chauhan MS, Baim DS, Ho KK, Popma JJ, Carrozza JP, et al. Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials. J Am Coll Cardiol. 2002;40:2082–2089
  15. Leon MB, Teirstein PS, Moses JW, Tripuraneni P, Lansky AJ, Jani S, et al. Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting. N Engl J Med. 2001;344:250–256
  16. Waksman R, Ajani AE, White RL, Chan R, Bass B, Pichard AD, et al. Five-year follow-up after intracoronary gamma radiation therapy for in-stent restenosis. Circulation. 2004;109:340–344
  17. Mishkel GJ, Moore AL, Markwell S, Shelton MC, Shelton ME. Long-term outcomes after management of restenosis or thrombosis of drug-eluting stents. J Am Coll Cardiol. 2007;49:181–184
  18. Alfonso F, Auge JM, Zueco J, Bethencourt A, Lopez-Minguez JR, Hernandez JM, et al. Long-term results (three to five years) of the Restenosis Intrastent: Balloon angioplasty versus elective Stenting (RIBS) randomized study. J Am Coll Cardiol. 2005;46:756–760
  19. Schuhlen H, Kastrati A, Mehilli J, Hausleiter J, Pache J, Dirschinger J, et al. Restenosis detected by routine angiographic follow-up and late mortality after coronary stent placement. Am Heart J. 2004;147:317–322
  20. Pache J, Dibra A, Schaut C, Schuhlen H, Dirschinger J, Mehilli J, et al. Sustained increased risk of adverse cardiac events over 5 years after implantation of gold-coated coronary stents. Catheter Cardiovasc Interv. 2006;68:690–695

 Funding for the conduct of the Sirolimus-Eluting Stent in De Novo Native Coronary Lesions (SIRIUS) trial, including management and analysis of the 5-year follow-up was provided by the Cordis Corporation, Warren, New Jersey, through a services contract with the Harvard Clinical Research Institute (Boston, Massachusetts). Funding for the statistical analysis of this substudy was provided by Cordis Corporation (Warren, New Jersey) through a research grant to the Harvard Clinical Research Institute (Boston, Massachusetts).

 Dr. Mauri has received honoraria from Abbott Vascular, Redwood City, California, Boston Scientific, Natick, Massachusetts, Cordis Corporation, Warren, New Jersey, and Medtronic Vascular, Santa Rosa, California, and either consulting fees or honoraria from Cordis, Warren, New Jersey, Boston Scientific, Natick, Massachusetts, Medtronic, Santa Rosa, California, and Abbott Vascular, Redwood City, California. Dr. Cohen is a full-time employee of Cordis Corporation, Warren, New Jersey. Dr. Moses has received consulting fees from Johnson & Johnson, Warren, New Jersey. Dr. Leon has received either consulting fees or honoraria from Cordis (Warren, New Jersey), Boston Scientific (Natick, Massachusetts), Medtronic (Santa Rosa, California), and Abbott Vascular (Redwood City, California).

PII: S0002-9149(10)01035-0

doi: 10.1016/j.amjcard.2010.04.039

American Journal of Cardiology
Volume 106, Issue 6 , Pages 774-779 , 15 September 2010

Article Tools

* Image Usage & Resolution